|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the predictions of our previous mathematical modeling approach, the potential benefit of IFN-γ- and/or IL-6-specific antibody-mediated cytokine neutralization was explored in C57BL/6 mice infected with the influenza A/PR/8/34 strain, which were subsequently infected with the <i>Streptococcus pneumoniae</i> strain TIGR4 on day 7 post influenza.
|
31474978 |
2019 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhanced cell-mediated IFNγ secreting influenza directed CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses (>40-fold) to homotypic and heterosubtypic influenza A virus and peptides.
|
31315253 |
2019 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFNγ is a key regulator of inflammatory responses but its role in influenza A virus (IAV) pathogenesis is unclear.
|
30390564 |
2019 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using small heparinised blood samples we were able to observe the longitudinal influenza-specific IFN-γ responses of ferrets infected with both seasonal subtypes of IAV and found a notable increase in influenza-specific IFN-γ responses in circulating peripheral blood within 8 days post-infection.
|
30192789 |
2018 |
|
Influenza A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Early airway IFN-γ levels as well as the induction of lung NK cell CD69 expression and IFN-γ production in response to IAV infection were significantly attenuated in TLR7-deficient hosts.
|
29497422 |
2018 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impaired cDC differentiation during IAV infection was independent of type I interferons (IFNs), IFN-γ, TNFα and IL-6 and was not due to an intrinsic dysfunction of cDC precursors.
|
30372491 |
2018 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this chapter, we describe molecular methods for examining necrosome activation in response to the cytokines TNF-α, IFN-β, and IFN-γ, and upon infection with influenza A virus (IAV).
|
30136233 |
2018 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model.
|
27769099 |
2017 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
In ELISpot assays cases had higher frequencies of IFNγ+ CD8+ T cells responding to pdm09 virus or conserved CD8 T cell-restricted influenza A virus epitopes, compared to controls.
|
29145441 |
2017 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phenomenon of released-activity. Reply on comment on Don et al.: Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model.
|
28036118 |
2017 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results showed that tucaresol: (1) increases influenza A virus-, gp 160 peptide-, and HLA alloantigen-stimulated proliferation as well as interleukin (IL)-2 and interferon gamma (IFN gamma) production by PBMC of HIV-infected individuals with higher CD4 counts (>500/microl) but had only a marginal immunomodulatory effect on PBMC of patients with lower CD4 counts (<500/microl); (2) did not modify IL-10 production; (3) augmented CD25 expression on mitogen-stimulated T cells of HC but not of HIV-infected individuals; and (4) marginally increased CTL activity.
|
11112360 |
2000 |